Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion
Comunicato Precedente
Comunicato Successivo
"In the third quarter, we saw strong sales growth in Sweden, while partner discussions are taking time as we work to secure the right commercial terms for the product," says Claus Egstrand, CEO.
Significant events during the quarter
Significant events after the quarter
Other events during and after the quarter
The full report is available at https://www.enzymatica.com/investors/financial-reports/
The information in this press release is such that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 CET on October 30, 2025.
For more information, please contact:
Claus Egstrand, CEO, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Enzymatica AB is headquartered in Lund and is listed on Nasdaq First North Growth Market. For more information, visit www.enzymatica.se.
Enzymatica's Certified Adviser is DNB Carnegie Investment Bank AB (publ).
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/enzymatica-ab/r/quarterly-report-q3-2025--strong-development-in-sweden-and-continued-focus-on-international-expansio,c4258856
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/enzymatica-ab-quarterly-report-q32025-strong-development-in-sweden-and-continued-focus-on-international-expansion-302599565.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




